Imiglucerase biosimilar - Harvest Moon Pharmaceuticals

Drug Profile

Imiglucerase biosimilar - Harvest Moon Pharmaceuticals

Alternative Names: Recombinant glucocerebrosidase - Harvest Moon Pharmaceuticals

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Glucosidases
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Gaucher's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Feb 2016 No recent reports on development identified - Phase-III for Gaucher's disease in Brazil (Parenteral)
  • 22 Aug 2013 Phase-III clinical trials in Gaucher's disease in Brazil (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top